Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis

Thornton J; Elliott R; Tully M P; Dodd M; Webb A K
March 2004
Thorax;Mar2004, Vol. 59 Issue 3, p242
Academic Journal
BACKGROUND: Several studies have suggested that clinical outcomes in adults with cystic fibrosis (CF) are equivalent after home and hospital treatment with intravenous antibiotics, but these studies were small and selective and only considered one course of treatment. METHODS: A retrospective longitudinal study was performed to compare the clinical outcome over a period of 1 year of all patients attending the Manchester Adult CF Unit who received intravenous antibiotics at home or in hospital. The primary outcome measure was percentage change in forced expiratory volume in 1 second (FEV(1)) at the end of the 1 year period. Baseline "best" and "average" FEV(1) values were established for each patient for the year before the study. The secondary outcome measures were percentage changes in forced vital capacity (FVC) and body weight. RESULTS: A total of 116 patients received 454 courses of intravenous antibiotics. At the end of 1 year there had been a mean percentage decline in FEV(1) compared with the baseline "average" for patients treated mostly at home but an improvement in patients treated mostly in hospital (Tukey's HSD mean difference 10.1%, 95% CI 2.9 to 17.2, p = 0.003). For all patients there was a mean percentage decline in FEV(1) from the baseline "best" value. For each course of treatment the mean percentage improvements in FEV(1) at the end of the course from the start of the course were significantly higher for patients treated in hospital than for those treated at home. CONCLUSIONS: Clinical outcome, as defined by spirometric parameters and body weight, was better after a course of treatment in hospital than after home treatment, and this benefit was maintained over 1 year of treatment. The results suggest that patients treated at home need closer supervision.


Related Articles

  • Changes in Pediatric Health-Related Quality of Life in Cystic Fibrosis After IV Antibiotic Treatment for Pulmonary Exacerbations. Modi, Avani C.; Lim, Crystal S.; Driscoll, Kimberly A.; Piazza-Waggoner, Carrie; Quittner, Alexandra L.; Wooldridge, Jamie // Journal of Clinical Psychology in Medical Settings;Mar2010, Vol. 17 Issue 1, p49 

    Intravenous (IV) antibiotic therapy for pulmonary exacerbations (PE) has been shown to improve pulmonary functioning for patients with cystic fibrosis (CF); however, little is known about its effects on pediatric health-related quality of life (HRQOL). This prospective study assessed the impact...

  • End-of-Life Care in Adults with Cystic Fibrosis. Philip, Jennifer A.M.; Gold, Michelle; Sutherland, Sharon; Finlayson, Felicity; Ware, Claire; Braithwaite, Maxine; Harris, Jane; Kotsimbos, Tom; Wilson, John F. // Journal of Palliative Medicine;Mar2008, Vol. 11 Issue 2, p198 

    Background: Cystic fibrosis (CF) is a life-limiting congenital disease, with most patients dying at a young age of progressive lung disease. Lung transplantation offers hope for many but may not occur. There is little to guide the provision of palliative care to this young population who...

  • Minocycline in the Antibiotic Regimen of Cystic Fibrosis Patients: Weight Gain and Clinical Improvement. Patterson, Paul R. // Clinical Pediatrics;Jan1977, Vol. 16 Issue 1, p60 

    Minocycline hydrochloride was given to 100 patients with cystic fibrosis of the pancreas for periods of 3 months over a broad-spectrum antibiotic drug rotation which lasted 2 years. Increased weight gain and some clinical improvement was seen during treatment with minocycline. Those patients...

  • Treatment of Aspergillus fumigatus in Patients with Cystic Fibrosis: A Randomized, Placebo-Controlled Pilot Study. Aaron, Shawn D.; Vandemheen, Katherine L.; Freitag, Andreas; Pedder, Linda; Cameron, William; Lavoie, Annick; Paterson, Nigel; Wilcox, Pearce; Rabin, Harvey; Tullis, Elizabeth; Morrison, Nancy; Ratjen, Felix // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Background: Many patients with cystic fibrosis develop persistent airway infection/colonization with Aspergillus fumigatus, however the impact of A. fumigatus on clinical outcomes remains unclear. The objective of this study was to determine whether treatment directed against Aspergillus...

  • Cystic fibrosis: clinical aspects.  // Thorax;Dec2004 Supplement, Vol. 59, p78 

    The article presents some papers related to clinical aspects of cystic fibrosis (CF). People with CF are at an increased risk of acquiring candidiasis. The study determines the prevalence of symptomatic candidiasis, the risk factors for infection, and the association between treatments received...

  • Evaluation of the Merlin, Micronaut System for Automated Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa and Burkholderia Species Isolated from Cystic Fibrosis Patients. Häussler, S.; Ziesing, S.; Rademacher, G.; Hoy, L.; Weiβbrodt, H. // European Journal of Clinical Microbiology & Infectious Diseases;Aug2003, Vol. 22 Issue 8, p496 

    Since accurate antimicrobial susceptibility testing of bacterial cystic fibrosis isolates is known to be problematic and an optimal in vitro testing method has not yet been evaluated, the study presented here was conducted to compare the performance of the reference agar dilution method and...

  • Antibiotic allergy in cystic fibrosis. Parmar, J. S.; Nasser, S. // Thorax;Jun2005, Vol. 60 Issue 6, p517 

    Allergic reactions to antibiotics are more common in cystic fibrosis (CF) than in the general population. This in part is due to the improving survival in adults with CF and the increased use of high, dose intravenous antibiotics. While some are immediate anaphylaxis type (IgE mediated)...

  • Simultaneous overexpression of multidrug efflux pumps in Pseudomonas aeruginosa non-cystic fibrosis clinical isolates. Poonsuk, Kanchana; Tribuddharat, Chanwit; Chuanchuen, Rungtip // Canadian Journal of Microbiology;Jul2014, Vol. 60 Issue 7, p437 

    The purpose of this study was to examine expression and regulation of 6 multidrug efflux systems, including MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY, MexJK, and MexVW, in 13 non-cystic fibrosis (CF) clinical isolates of Pseudomonas aeruginosa. These isolates displayed a high level of resistance...

  • Genetic relatedness and host specificity of Pseudomonas aeruginosa isolates from cystic fibrosis and non-cystic fibrosis patients. AbdulWahab, Atqah; Taj-Aldeen, Saad J.; Ibrahim, Emad; Abdulla, Shaikha H.; Muhammed, Ramees; Ahmed, Irshad; Abdeen, Yasmine; Sadek, Omnia; Abu-Madi, Marawan // Infection & Drug Resistance;2014, Vol. 7, p309 

    Background: Pseudomonas aeruginosa is one of the primary pathogens isolated more frequently in cystic fibrosis (CF) and it exhibits innate resistance to a wide range of antibiotics. Purpose: We sought to determine whether the highly prevalent genotypes of P. aeruginosa are specifically linked to...


Read the Article


Sign out of this library

Other Topics